Ro Orchestrates Branded GLP-1 Access

This setup turns branded GLP-1 access into a software and care experience business, not a pharmacy inventory business. Ro keeps the patient login, intake, clinician messaging, insurance checks, dose changes, and subscription relationship, while Novo Nordisk supplies the drug and CenterWell ships it. That lets Ro sell branded Wegovy inside its own workflow without owning stock, managing manufacturer contracts, or adding more pharmacy complexity to every order.

• The practical workflow is that a patient starts in Ro, completes the obesity intake, gets reviewed by a clinician, and pays through a Ro managed flow, but the actual branded prescription is routed into Novo Nordisk’s NovoCare channel and fulfilled by CenterWell. Ro stays visible to the patient even though the supply chain sits elsewhere.
  1 sacra 2 sacra
• This is also a response to the post shortage market. After compounded GLP-1s became less viable, Ro and other telehealth players needed legitimate branded supply. Ro’s manufacturer linked channel brought Wegovy down to a flat $499 per month and accounted for more than half of its GLP-1 business by mid 2025.
  2 sacra 3 sacra
• The competitive effect is that drug access becomes standardized across Ro, Hims & Hers, and LifeMD when Novo gives all three the same branded Wegovy price. That pushes competition back to who gives the smoothest long term care loop. Noom competes with coaching and tracking around weight loss, while Virta sells employers a heavier outcomes based program instead of a consumer front door.
  1 sacra 3 sacra 4 sacra

This points toward a market where telehealth winners look more like care orchestration layers sitting on top of manufacturer and pharmacy rails. Ro is building toward that role, and the next step is to use the same front end position to win more branded drug launches, deepen employer offerings, and make its care subscription valuable even when the medication itself is no longer scarce.